Review summarizes Aβ-targeted Alzheimer's vaccine progress from failed first-generation to promising next-generation candidates

Photo by Mika Baumeister / Unsplash

Frontiers in Medicine Published April 8, 2026 Medically reviewed May 1, 2026 DOI ↗ By Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

Key Takeaway

Consider Aβ-targeted Alzheimer's vaccines as investigational; next-generation candidates show early promise but lack proven clinical efficacy.

This systematic review synthesizes research progress on Aβ-targeted vaccines for Alzheimer's disease, covering first-generation and next-generation approaches including peptide/epitope vaccines, DNA vaccines, viral vector vaccines, and protein self-assembling vaccines. The review reports that the first-generation Aβ vaccine AN-1792 failed clinically due to autoimmune complications. In contrast, next-generation vaccines in preclinical studies have shown reduced Aβ deposition and improved cognitive function, while early clinical trials report favorable safety and immunogenicity profiles.

Specific numerical data on effect sizes, absolute numbers, p-values, or confidence intervals were not reported in the review. The safety assessment notes autoimmune complications for the first-generation AN-1792 vaccine, but adverse events, serious adverse events, discontinuations, and tolerability data for next-generation vaccines were not reported. Key limitations of the evidence were not explicitly detailed in the review.

From a practice perspective, this review summarizes research progress rather than providing definitive clinical guidance. The findings highlight that while next-generation Aβ-targeted vaccines show preclinical promise and early clinical safety signals, their clinical efficacy for Alzheimer's disease remains unestablished. Challenges including blood-brain barrier penetration, immune modulation, and defining optimal therapeutic windows require further investigation before clinical application can be considered.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

BackgroundAlzheimer’s disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive impairment, with the β-amyloid protein (Aβ) aggregation as a core pathological driver. As global aging intensifies, AD poses a severe public health burden, highlighting the urgency of developing effective immunotherapies. This review aims to systematically summarize the research progress of Aβ-targeted AD vaccines, from first-generation approaches to next-generation strategies, and discuss key challenges and future directions for clinical translation.MethodsA comprehensive literature search was conducted across PubMed, Web of Science, the Cochrane Library, EMBASE, and Google Scholar up to 14 November 2025. Relevant studies were selected using predefined eligibility criteria, focusing on Aβ-targeted AD vaccines’ development, mechanisms, preclinical efficacy, and clinical outcomes. Review articles and meta-analyses were included, while case reports and non-Aβ-targeted studies were excluded. Data extraction and synthesis focused on vaccine strategies, immune mechanisms, and translational challenges.ResultsFirst-generation Aβ vaccine (e.g., AN-1792) showed preclinical promise but failed clinically due to autoimmune complications. Next-generation vaccines, including peptide/epitope vaccines, DNA vaccines, viral vector vaccines, and protein self-assembling vaccines, have been developed to induce protective Th2-biased immune responses while avoiding harmful T-cell reactions. Preclinical studies demonstrate reduced Aβ deposition and improved cognitive function, with several candidates advancing to clinical trials showing favorable safety and immunogenicity. Key mechanisms include Fc receptor-mediated phagocytosis, antibody-mediated fibril disaggregation, and the peripheral Aβ sink effect.ConclusionAβ-targeted AD vaccines have evolved toward safer and more effective designs, with multiple strategies showing translational potential. Challenges remain, including blood-brain barrier (BBB) penetration, immune response modulation, and defining optimal therapeutic time windows. Future research should focus on personalized vaccines, combination therapies, and novel antigen delivery platforms to fully realize the clinical potential of AD immunotherapies.